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Background: Hemolysis is the most frequent and potentially one of the most harmful causes of poor 
sample quality. Many strategies have been attempted for minimizing the risk of generating spurious 
hemolysis during blood collection, such as using the HOLDEX® single-use holder, which features a chamber 
that decelerates blood flow pressure before entering evacuated blood tubes. We have hence designed a 
study to establish whether the new VACUETTE® SAFELINK, which shares different structure but similar 
strategy affecting blood flow pressure, may ensure a comparable sample quality as using HOLDEX® single-
use holder.
Methods: A total number of 24 clinical chemistry, hematologic and hemostasis parameters were measured 
in paired blood samples collected from 30 healthy volunteers using either HOLDEX® single-use holder or 
VACUETTE® SAFELINK. Test results were compared with paired Student’s t-test, Pearson’s correlation 
and Bland-Altman plots.
Results: All test results were non-significantly different in blood samples collected with HOLDEX® single-
use holder or VACUETTE® SAFELINK except potassium, whose values were marginally higher in plasma 
collected with VACUETTE® SAFELINK. All Pearson’s correlation coefficients were excellent except 
potassium, chloride and H-index. In this latter case, the correlation did not reach statistical significance. 
The percent bias of different parameters in samples collected with HOLDEX® single-use holder or 
VACUETTE® SAFELINK was minimal, comprised between −4.5% and +1.6%. In all cases the percent 
bias was comprised within the quality specifications tests. The rate of plasma samples with H-index >3 was 
eventually lower when blood was collected using SAFELINK than with HOLDEX® single use holder (odds 
ratio, 0.52; 95% confidence interval, 0.17–1.60). 
Conclusions: The results of this comparative study suggest that sample quality is thoughtfully comparable 
using HOLDEX® single-use holder and VACUETTE® SAFELINK, thus translating into the concept that 
VACUETTE® SAFELINK may also be an effective means for reducing spurious hemolysis, especially when 
drawing blood from catheters.
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Introduction
Laboratory diagnostics has become a virtually unavoidable 
part of the clinical decision making in recent years (1). 
This essential medical discipline can be reasonably defined 
as the science of providing valuable clinical information 
by analyzing the concentration or composition of many 
analytes in different body fluids (2). This clear-cut definition 
has been inherently associated with a straightforward 
partitioning of the total testing process into—at least—three 
different parts, which entail the preanalytical, analytical 
and postanalytical phases (3). Several lines of evidence now 
attest that many manually-intensive preanalytical activities 
are highly vulnerable to errors and uncertainties (4), so that 
major efforts shall be made to enhance both quality and 
safety of this essential part of the total testing process (5). 
Until in vivo diagnostic testing will replace laboratory 
diagnostics, but there is no reliable evidence that this 
may happen soon, blood samples collection will remain 
an unavoidable part of the total testing process for long. 
The collection of quality samples would hence necessitate 
that the entire blood drawing procedure is accurately 
standardized and appropriately performed, by thoughtfully 
applying currently available recommendations and 
guidelines (6). This also encompasses that the different 
materials used for drawing blood will need to fulfill strict 
quality criteria. Notably, the recent recommendations of the 
European Federation of Clinical Chemistry and Laboratory 
Medicine (EFLM) also clearly endorse that an analytical and 
clinical validation is necessary before new blood collection 
devices are introduced into clinical practice (7).
Previous evidence has been published that the HOLDEX® 
single-use holder (Greiner Bio-One GmbH, Kremsmuenster, 
Austria) may be effective to lower the risk of generating 
spurious hemolysis during blood drawing (8). This promising 
evidence has been attributed to the specific conformation 
of the device, characterized by the presence of an eccentric 
luer on the top which may effectively reduce the differential 
of pressure between the evacuated blood tube and the 
vein, especially when blood is drawn through catheters. 
More recently, Greiner Bio-One has manufactured a new 
type of holder (VACUETTE® SAFELINK, Greiner Bio-
One GmbH, Kremsmuenster, Austria), which is supposed 
to allow efficient and practical handling, along with eased 
and more rapid blood drawing when used in combination 
with blood sampling devices encompassing a standardized 
female luer lock adapter. Unlike HOLDEX® single-use 
holder, which is characterized by the integrated luer needle 
with off-centre luer slip connector, the luer lock mechanism 
in VACUETTE® SAFELINK is centered at the top of 
the holder, but the device still contains a small chamber 
which allows seeing the flash of vein penetration and also 
has the effect of decelerating blood flow prior to entering 
the tube, thus potentially reducing the risk of spurious 
hemolysis during blood drawing and ultimately enhancing 
sample quality. In accordance with the recent EFLM 
recommendations (7), we have hence designed a comparative 
study to establish whether VACUETTE® SAFELINK may 
ensure comparable sample quality as using HOLDEX® 
single-use holder.
Methods
The study population consisted of 30 healthy volunteers 
recruited from the local laboratory staff (15 women and 
15 men; mean age, 38±14 years), regularly undergoing 
laboratory testing and health assessment visits for 
establishing the fitness for job. The protocol of the study was 
based on two sequential venipunctures. The first standard 
venipuncture was performed by an expert phlebotomist on 
one arm, using a 19 gauge (G) straight luer needle attached 
to a Greiner HOLDEX® single-use holder, whilst the second 
venipuncture was then sequentially performed on the other 
arm, also using a 19 G straight luer needle, but attached to 
the new Greiner VACUETTE® SAFELINK holder. Three 
sequential blood tubes were drawn in each venipuncture, 
containing lithium-heparin, K2EDTA (dipotassium 
ethylenediaminetetraacetic acid) and 3.2% buffer sodium 
citrate (all from Greiner Bio-One GmbH, Kremsmuenster, 
Austria). The new disposable VACUETTE® SAFELINK 
holder with male luer lock is manufactured with unbreakable 
plastic and does not contain natural rubber latex. The specific 
luer lock mechanism grants secure connection and has the 
advantages of being compatible with the vast majority of 
female luer lock adapters and can sustain blood pressures as 
high as 185 mmHg.
Clinical chemistry and immunochemistry testing was 
performed in lithium-heparin plasma, using Roche Cobas 
8000 and proprietary reagents (Roche Diagnostics, Basel, 
Switzerland). Specifically, aspartate aminotransferase 
(AST) was measured using the International Federation 
of Clinical Chemistry and Laboratory Medicine (IFCC) 
assay with pyridoxal phosphate activation, lactate 
dehydrogenase (LDH) with the reference UV assay, 
whilst sodium, potassium and chloride were tested with an 
indirect method using ion-selective electrodes. The serum 
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indices, thus including the hemolysis-index (H-index), 
icteric-index (I-I) and lipaemic-index (L-I) were also 
assayed using Roche Cobas 8000, with spectrophotometric 
techniques, as comprehensively described elsewhere (9). 
The complete blood cell count was performed in whole 
blood anticoagulated with K2EDTA, using Sysmex 
XN (Sysmex Corporation, Kobe, Japan), whose basic 
characteristics have been previously described elsewhere 
(10,11). Routine hemostasis testing, thus including 
prothrombin time (PT), activated partial thromboplastin 
time (APTT), fibrinogen and D-dimer, was assayed 
in citrate plasma, using Instrumentation Laboratory 
ACL TOP 700 (Instrumentation Laboratory, Bedford, 
MA, USA) and proprietary reagents (RecombiPlasTin, 
SynthASil, Fibrinogen-CXL and HemosIL HS D-dimer). 
The characteristics of this analyzer and reagents have 
been earlier summarized elsewhere (12). Finally, thrombin 
generation (TG) was assayed in citrate plasma, using the 
fully-automated analyzer ST Genesia (STG-BleedScreen; 
Diagnostica Stago, Asnières sur Seine, Cedex, France), as 
previously summarized (13). These measurements included 
the assessment of lag phase (or lag time), time to reach 
the peak (or time to peak), peak height and endogenous 
thrombin potential (ETP). 
The test results in samples collected with the two 
different holders followed a substantial ly normal 
distribution, as assessed with Kolmogorov-Smirnov test, 
and were hence expressed as mean and standard deviation 
(SD) and compared with paired Student’s t-test, Pearson’s 
correlation and Bland-Altman plots, using Analyse-it 
(Analyse-it Software Ltd, Leeds, UK). The mean percent 
bias of values in samples collected with the two different 
holders was compared with the quality specifications 
calculated from desirable biological variation (14). All 
subjects participating to this study provided a written 
informed consent and the study was cleared by the local 
Ethics Committee (970CESC; July 20, 2016).
 
Results
The main results of this study are shown in Table 1. 
All test results of hematological, clinical chemistry and 
hemostasis testing were non-significantly different in blood 
samples collected with HOLDEX® single-use holder or 
VACUETTE® SAFELINK except for potassium, whose 
values were marginally higher in plasma collected with 
VACUETTE® SAFELINK. The Pearson’s correlation 
of the different parameters in blood samples collected 
with HOLDEX® single-use holder or VACUETTE® 
SAFELINK is shown in Table 2. All correlation coefficients 
were excellent except for potassium, chloride and, 
Table 1 Comparison of laboratory test results in samples collected 
with Greiner Bio-One HOLDEX® single-use and VACUETTE® 
SAFELINK holders
Parameter HOLDEX® SAFELINK P
Complete blood cell count
Red blood cells (×1012/L) 4.70±0.50 4.67±0.47 0.099
Hemoglobin (g/L) 137.6±16.9 136.9±16.5 0.070
Hematocrit 0.42±0.05 0.42±0.04 0.134
Mean corpuscular volume (fL) 89.0±6.2 89.2±6.1 0.081
RDW (%) 13.0±1.2 13.0±1.2 0.339
White blood cells (×109/L) 6.27±1.80 6.16±1.81 0.054
Platelets (×109/L) 275±64 272±65 0.261
Mean platelet volume (fL) 10.7±1.1 10.7±1.1 0.354
Clinical chemistry
Potassium (mmol/L) 4.38±0.24 4.49±0.23 0.011
Chloride (mmol/L) 100.2±1.4 100.7±1.9 0.114
Sodium (mmol/L) 140.4±2.0 140.1±1.8 0.326
Aspartate aminotransferase 
(U/L)
20.5±6.9 20.7±7.2 0.508
Lactate dehydrogenase (U/L) 160.1±26.3 160.9±27.3 0.273
Hemostasis
Prothrombin time (sec) 11.46±0.77 11.45±0.73 0.792
Activated partial 
thromboplastin time (sec)
30.23±2.04 30.46±2.46 0.362
Fibrinogen (g/L) 2.55±0.42 2.56±0.47 0.740
D-dimer (ng/L) 69.5±43.2 69.8±47.5 0.920
TG-lag time (sec) 2.88±0.64 2.90±0.65 0.532
TG-peak height (nM) 197±88 201±97 0.556
TG-time to peak (sec) 6.12±1.17 6.10±1.18 0.731
TG-endogenous thrombin 
potential (nM)
1,281±348 1,280±369 0.965
Sample quality
H-index 4.9±2.5 4.5±1.8 0.459
I-Index 22.7±8.9 22.6±8.6 0.639
L-index 9.4±4.5 9.3±5.2 0.823
RDW, red blood cell distribution width; TG, thrombin generation.
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Table 2 Comparison of laboratory test results in samples collected with Greiner Bio-One HOLDEX® single-use and VACUETTE® SAFELINK 
holders
Parameter Correlation Quality specifications (%) Bias (%)
Complete blood cell count
Red blood cells (×1012/L) 0.982 (P<0.001) 1.7 −0.6 (−1.3 to 0.2)
Hemoglobin (g/L) 0.991 (P<0.001) 1.8 −0.5 (−1.2 to 0.1)
Hematocrit 0.976 (P<0.001) 1.7 −0.6 (−1.7 to 0.4)
Mean corpuscular volume (fL) 0.997 (P<0.001) 1.3 0 (−0.2 to 0.2)
RDW (%) 0.995 (P<0.001) 1.7 0.2 (−0.2 to 0.5)
White blood cells (×109/L) 0.986 (P<0.001) 6.1 −1.9 (−3.9 to 0.2)
Platelets (×109/L) 0.983 (P<0.001) 5.9 −1.0 (−2.7 to 0.7)
Mean platelet volume (fL) 0.993 (P<0.001) 2.3 0.2 (−0.3 to 0.7)
Clinical chemistry
Potassium (mmol/L) 0.532 (P=0.002) 1.8 1.6 (0.7 to 2.5)
Chloride (mmol/L) 0.572 (P=0.001) 0.5 0.5 (−0.1 to 1.0)
Sodium (mmol/L) 0.770 (P<0.001) 0.2 −0.2 (−0.5 to 0.2)
Aspartate aminotransferase (U/L) 0.953 (P<0.001) 6.5 0.9 (−3.5 to 5.4)
Lactate dehydrogenase (U/L) 0.974 (P<0.001) 4.3 1.0 (−6.6 to 8.6)
Hemostasis
Prothrombin time (sec) 0.963 (P<0.001) 2.0 −0.1 (−0.7 to 0.6)
Activated partial thromboplastin time (sec) 0.828 (P<0.001) 2.3 0.7 (−1.0 to 2.3)
Fibrinogen (g/L) 0.933 (P<0.001) 4.8 0.1 (−2.3 to 2.5)
D-dimer (ng/L) 0.953 (P<0.001) 8.8 −3.3 (−14.9 to 8.4)
TG-lag time (sec) 0.958 (P<0.001) N/A 0.8 (−1.5 to 3.1)
TG-peak height (nM) 0.931 (P<0.001) N/A 0.8 (−6.6 to 8.2)
TG-time to peak (sec) 0.976 (P<0.001) N/A −0.3 (−2.0 to 1.4)
TG-endogenous thrombin potential (nM) 0.860 (P<0.001) N/A −0.5 (−6.7 to 5.7)
Sample quality
H-index 0.122 (P=0.521) N/A −4.5 (−23.8 to 14.8)
I-Index 0.922 (P<0.001) N/A −0.1 (−1.9 to 1.7)
L-index 0.885 (P<0.001) N/A −0.3 (−7.8 to 7.5)
N/A, not available; RDW, red blood cell distribution width; TG, thrombin generation.
especially, H-index. In this latter case, the correlation did 
not even reach statistical significance. The percent bias 
of the different parameters in blood samples collected 
with HOLDEX® single-use holder or VACUETTE® 
SAFELINK was always minimal, ranging between −4.5% 
for the H-index and +1.6% for potassium (Table 2). In all 
cases the percent bias was comprised within the quality 
specifications. Importantly, the rate of samples with H-index 
>3 was marginally lower when blood was collected using 
VACUETTE® SAFELINK than with HOLDEX® single-
use holder (i.e., 19/30 versus 23/30; odds ratio, 0.52; 95% 
CI, 95 0.17–1.60; P=0.263). 
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Discussion
Blood sample quality is essential to guarantee reliable 
results of downstream laboratory testing (15). Among 
the various sources of preanalytical mistakes, hemolysis 
is indeed the most frequent and one of the most harmful 
when overlooked or left unmanaged (16). Several strategies 
have been attempted to minimize the risk of producing 
spurious hemolysis during blood collection, such as using 
discard or low vacuum tubes (17), decreasing the pressure 
of blood aspiration within the tube (18), use of new venous 
catheter blood draw devices (19), as well as the usage of 
holders with features that effectively decelerate blood flow 
pressure (8). VACUETTE® SAFELINK is one of these 
last devices, which has been recently commercialized by 
Greiner Bio-One GmbH, with the aim of lowering the risk 
of generating spurious hemolysis during blood drawing, 
and thereby improving clinical effectiveness by reducing 
the number of hemolyzed tests suppressed and avoiding 
the need to recollect blood samples. This innovative device 
is equipped with a small flash chamber which has two 
effects: allowing to visualize the blood and decelerating 
blood flow pressure before entering the tube. Altogether 
these two characteristics would enable the phlebotomist 
to enhance the rate of successful venipunctures and 
contextually lowering the risk of hemolyzing samples. To 
validate this second theoretical advantage, we planned a 
comparative study, where 24 clinical chemistry, hematology 
and hemostasis test results were compared among samples 
collected using the HOLDEX® single-use holder or the 
new VACUETTE® SAFELINK holder. 
Taken together, the results of our study clearly 
suggest that the performance of these two devices is fully 
comparable. More specifically, the values of all analytes 
tested (except potassium) were non-significantly different 
in blood samples collected with either holder and, even 
more importantly, in no case the percent bias exceeded the 
currently quality specifications. The correlation between 
measures was also optimal except for potassium, chloride 
and, especially, for the H-index. Albeit the correlation of 
potassium and chloride plasma concentrations was still 
significant and thereby acceptable, H-index values obtained 
with HOLDEX® single-use holder and VACUETTE® 
SAFELINK were definitely incomparable (r=0.122; 
P=0.521), with VACUETTE® SAFELINK exhibiting a 
trend towards lower risk of generating spurious hemolysis 
(i.e., −48%). This is not really unexpected, and may be 
either due to the small sample size or to the different 
structure of the two devices, with HOLDEX® single-use 
holder presenting an eccentric position of the luer slip 
connection, compared to the luer centered at the top of 
the holder in VACUETTE® SAFELINK. This would 
inevitably generate a different path of blood flow within 
the two devices, thus explaining the different predisposition 
towards in vitro erythrocyte injury depending on flow 
perturbation and erythrocyte mechanical fragility (20). After 
that said, however, the data obtained in our experimental 
study clearly show that the quality of laboratory testing is 
virtually identical between HOLDEX® single-use holder 
and VACUETTE® SAFELINK (Table 2), whilst the risk 
of injuring blood cells appears eventually lower with 
VACUETTE® SAFELINK. Of particular note are also the 
results of the TG assay, which would enable us to reliably 
conclude that hemostasis may be equally safeguarded with 
both devices.
Conclusions
In conclusion, the results of this comparative study 
suggest that sample quality is thoughtfully comparable 
using HOLDEX® single-use holder and VACUETTE® 
SAFELINK, thus translating into the concept that 
VACUETTE® SAFELINK may also be an effective means 
for reducing spurious hemolysis, especially when drawing 
blood from catheters.
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